

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage, via Express Mail label no. EU 633725128 US addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Dated: 12/29/03

Signature: [Signature] (Lisa Small)

SWISS LAW GROUP DOCKET NO. 42837-20010.21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application:

Examiner S. Patel

Art Unit 1624

Commissioner for Patents
P.O. Box 1450
Mail Stop PATENT APPLICATION
Alexandria, VA 22313-1450

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. 10/251,442 filed on September 20, 2002.

Andrei W. KONRADI, Michael A. PLEISS, Eugene D. THORSETT, Susan ASHWELL, Gregory S. WELMAKER, Anthony KREFT, Dimitrios SARANTAKIS, Darren B. DRESSEN, Francine S. GRANT, of Christopher SEMKO and Ying-Zi XU

(inventor(s) currently of record in prior application)

for HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

(title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	1	- 20	0	\$18.00 each	\$ 0.00
Independent	1	- 3	0	\$86.00 each	\$ 0.00
Minimum Fee					\$ 770.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 0.00
Total					\$ 770.00
Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					\$ 0.00
Total Filing Fee					\$ 770.00

2. ☐ Please charge the required fee to Swiss Law Group Deposit Account No. 50-2859. A copy of this sheet is enclosed.
3. ☒ Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. 10/251,442, filed September 20, 2002.

- 4a. ☐ New formal drawings are enclosed.
- 4b. ☐ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
- 6. ☒ The prior application is assigned of record to Elan Pharmaceuticals, Inc. and American Home Products Corporation.
- 7a. ☒ A copy of the Power of Attorney filed in the prior application no. 10/251,442, filed September 20, 2002 is enclosed.
- 7b. ☒ Please cancel in this application, original Claims 2-74 of the prior application before calculating the filing fee.
- 8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
- 9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no. .
- 10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- 11. ☐ Additional enclosures or instruction

Respectfully submitted,

Date 12/29/03

Lorna L. Tanner 50,782
 Lorna L. Tanner (Reg. No.)
 SWISS LAW GROUP
 Building 3, Palo Alto Square
 3000 El Camino Real, Ste. 100
 Palo Alto, CA 94306